Navigation Links
Dey L.P. to Market EMSAM(R) Skin Patch for Treatment of Major Depressive Disorder
Date:5/29/2009

PITTSBURGH, May 29 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today announced that it has begun to market and distribute EMSAM(R) in the U.S. EMSAM, a selegiline transdermal system, is a monoamine oxidase inhibitor (MAOI), which was approved by the U.S. Food and Drug Administration (FDA) in 2006 for the treatment of major depressive disorder.

EMSAM previously was marketed and distributed by Bristol-Myers Squibb through a commercialization agreement. The transfer of distribution, marketing and sales to Dey concludes the three-year agreement with Bristol-Myers. Manufactured by Mylan subsidiary Mylan Technologies Inc. (MTI), EMSAM is a registered trademark of Somerset Pharmaceuticals Inc. In July 2008, Mylan acquired Watson Pharmaceutical Inc.'s 50 percent interest in Somerset, making the proprietary research and development company a wholly-owned subsidiary of Mylan.

Dey President Carolyn Myers, Ph.D., said, "I am very pleased that we have the opportunity to bring the marketing and distribution of EMSAM back into the Mylan family of companies. EMSAM was developed by Somerset in collaboration with Mylan and is manufactured by MTI. Now, we can market and distribute this important product through our specialty division, Dey, and the entire supply and distribution process will benefit from additional efficiencies and cost synergies going forward."

Dey, a Mylan company, is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey puts patients first through its development of innovative and affordable therapies. For more information on Dey or its products,
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
3. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
4. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
5. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
6. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
7. DNA Sequencing Equipment Market to Fragment and Grow as Competition, New Technologies Develop
8. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
9. Dental Implant Market Insights Webinar
10. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
11. XTL to Appeal NASDAQ Staff Determination; XTL May Transfer its ADR Listing to the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and Chief Executive Officer of Neurocrine Biosciences, will ... Miami.   The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
(Date:3/3/2015)... Santa Clara, California (PRWEB) March 03, 2015 ... and development service company, has launched a new Life ... research reagents for preclinical research. , The first ... monoclonal antibody isotype controls, and soon to be released ... The company will continue to expand their life science ...
(Date:3/3/2015)... MA (PRWEB) March 03, 2015 HubCast® ... Supply Chain, today announced the expansion of its Global ... color-matched print to 850 the world’s largest cities across ... Chain extends to 137 countries providing global enterprises ease, ... print procurement process from online order to real-world delivery ...
(Date:3/3/2015)... , March 3, 2015 AtheroNova Inc. (OTCQB: ... Operations, Inc., filed voluntary petitions under Chapter 11 of the ... of California , Santa Ana ... The Company,s Chapter 11 cases are expected to be jointly ... a Bankruptcy Court supervised asset sale process, for all or ...
Breaking Biology Technology:Crown Bioscience Launches Life Science Product Catalog 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... The Board of,Directors, meeting today under the chairmanship of Albert Saporta, approved,STALLERGENES, half year consolidated financial statements:, (EUR millions) ... ... % ... change, Sales ...
... NLTX ), today announced that Peter Strumph, Chief ... the Biotech Industry,conference on Thursday, September 4, at 1:30 ... City. Mr. Strumph will provide a company,overview and update ... The presentation will be webcast live and can be ...
... Aug. 27 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... that Jerry McMahon, Ph.D., chairman and CEO,will participate ... he,will provide a corporate overview, including a discussion ... lead product candidate., -- The Thomas Weisel ...
Cached Biology Technology:Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 3Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2Poniard Pharmaceuticals Announces Upcoming Conference Participation 2
(Date:2/18/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that its ... investors to participate via webcast. , Cowen and Company ... March 3, 2015 at 11.20 a.m. Eastern Time , ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... for these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/12/2015)... , Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62/113114 for DISTRIBUTED METHOD AND ... The patent further establishes NXT-ID,s position in the ... property portfolio the ability for multiple devices to collaborate ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... of Rostock in Germany has developed a new way to ... using less energy than before. It,s expected that this breakthrough ... diverse range of applications; including transport and medical devices. ... open access journal Materials Today , reports on the ...
... research by UM bioclimatology Assistant Professor Ashley Ballantyne ... Arctic temperatures during the Pliocene era. His research ... the July issue of Nature Geoscience. The full ... Palaeoecology: An International Journal for the Geosciences ., ...
... sector, are accessible marine resources as they grow in ... every year and have become an important part of ... based on macroalgae for bioenergy, cosmetics and biomedicine. , ... led by the Spanish National Research Council (CSIC) that ...
Cached Biology News:Cool it, quick: Rapid cooling leads to stronger alloys 2Japan, China and South Korea account for 84 percent of the macroalgae patents 2
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
STX18 Immunogen: STX18 (NP_058626, 101 a.a. ~ 200 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Request Info...
Biology Products: